← Back to jobs

Director, Target Validation Sciences

Takeda Pharmaceutical Company Ltd
FULL_TIME Remote · US Boston, MA, US Posted: 2026-05-11 Until: 2026-06-10
Apply Now →
You will be redirected to the original job posting on BeBee.
Apply directly with the employer.
Job Description
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms of Use. I further attest that all information I submit in my employment application is true to the best of my knowledge. Job Description Objective / Purpose: The Director, Target Validation Sciences will lead a next-generation, automation-enabled assay hub for human disease–relevant target validation. Working closely with the Lab of Tomorrow (Takeda’s lab automation and digitalization initiative), this role will transform how target validation is conducted by integrating advanced 3D disease models, organ-on-a-chip technologies, automation, and AI-enabled data analytics into scalable, decision-driving platforms. This role will contribute to and help shape the scientific direction of target validation across therapeutic areas, modernize workflows through digitalization, and support assay transfer across functions while driving the standardization and centralization of assay platforms, accelerating portfolio progression. Accountabilities: Establish and grow a center of excellence for human disease–relevant assay platforms, integrating advanced 3D tissue culture systems, organ-on-chip technologies, and automation-enabled approaches to support scalable target validation. Own and drive cross-functional assay transfer and standardized workflows (including SOP frameworks), partnering with platform teams to ensure reproducibility, scalability, and data quality across target validation platforms. Provide scientific and strategic leadership in target validation for GI inflammatory/fibrotic diseases, oncology, and Neuroscience, including development of novel, disease-relevant assays that translate mechanistic biology into decision-drivi